Chinese EV Stocks Slide as December Sales Growth Slows, Raising Demand Concerns 
Intel Unveils Panther Lake AI Laptop Chips at CES 2025, Marking Major 18A Manufacturing Milestone 
Tesla UK Sales Slide as Competition Intensifies, While BYD Surges in Electric Vehicle Market 
AMD Unveils Next-Generation AI and PC Chips at CES, Highlights Major OpenAI Partnership 
BTIG Initiates Buy on SoftBank as AI and Robotics Strategy Gains Momentum 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Cathay Pacific Shares in Focus as Air China Plans Major Stake Reduction 
Dell Revives XPS Laptop Lineup With New XPS 14 and XPS 16 to Boost Premium PC Demand 
Samsung Electronics Hits Record High as AI Momentum Fuels Investor Optimism 
Samsung Electronics Poised for Massive Q4 Profit Surge on Soaring Memory Chip Prices 
U.S. Airline Flight Cancellations Surge After Venezuela Military Operation and FAA Airspace Closures 
SMIC Shares Climb as China Boosts Chipmaking Support Amid AI Optimism 
Saks Global Enterprises Seeks $1 Billion Loan Amid Possible Chapter 11 Bankruptcy Filing 
TSMC Shares Hit Record High as Goldman Sachs Raises Price Target on AI Demand Outlook 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Kia Targets 3.35 Million Global Vehicle Sales in 2026 Amid Steady Growth Outlook 
EMERYVILLE, Calif., March 15, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will provide a corporate overview at the Oppenheimer 27th Annual Healthcare Conference, taking place March 21-22, 2017, in New York, NY.
| Zogenix Presentation Details | |
| Date: | Wednesday, March 22, 2017 |
| Time: | 2:10 pm Eastern Time / 11:10 am Pacific Time |
| Location: | New York, NY - Westin New York Grand Central Hotel |
The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
